References
- Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. [2016 Nov 12];66(6):443–459. doi: 10.3322/caac.21357
- Morschhauser F, Zinzani PL, Kröger N, et al. Indolent lymphomas. EBMT/EHA CAR-T cell handbook. Cham: Springer; 2022. Chapter 15. 2022 Feb.
- Huet S, Sujobert P, Salles G. From genetics to the clinic: a translational perspective on follicular lymphoma. Nat Rev Cancer. 2018 Apr;18(4):224–239. doi: 10.1038/nrc.2017.127
- de Weers M, Brouns GS, Hinshelwood S, et al. B-cell antigen receptor stimulation activates the human Bruton’s tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem. [1994 Sep 30];269(39):23857–23860. doi: 10.1016/S0021-9258(19)51014-6
- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516. doi: 10.1056/NEJMoa1306220
- Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. [2020 Nov 24];4(22):5773–5784. doi: 10.1182/bloodadvances.2020003121
- Treon SP, Meid K, Gustine J, et al. Long‐term follow‐up of Ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstrom Macroglobulinemia. J Clin Oncol. 2021;39(6):565‐575. doi: 10.1200/JCO.20.00555
- Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):336–345. doi: 10.1182/hematology.2020000118
- Gomez EB, Ebata K, Randeria HS, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. [2023 Jul 6];142(1):62–72. doi: 10.1182/blood.2022018674
- Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. [2021 Mar 6];397(10277):892–901. doi: 10.1016/S0140-6736(21)00224-5
- Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as treatment for patients with Relapsed/Refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J Clin Oncol. [2018 Aug 10];36(23):2405–2412. doi: 10.1200/JCO.2017.76.8853
- Zinzani PL, Mayer J, Flowers CR, et al. ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol. [2023 Nov 20];41(33):5107–5117. doi: 10.1200/JCO.23.00775
- Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. [2015 Aug 10];33(23):2516–2522. doi: 10.1200/JCO.2014.59.7534
- Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-Cell diffuse large B-Cell Lymphoma. J Clin Oncol. [2019 May 20];37(15):1285–1295. doi: 10.1200/JCO.18.02403
- Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug;21(8):922–926. doi: 10.1038/nm.3884
- Graf SA, Cassaday RD, Morris K, et al. Ibrutinib monotherapy in relapsed or refractory, transformed diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):176–181. doi: 10.1016/j.clml.2020.11.023
- Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. [2014 Mar 13];370(11):1008–1018. doi: 10.1056/NEJMoa1314583
- Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in Mantle-cell lymphoma. N Engl J Med. [2017 Sep 28];377(13):1250–1260. doi: 10.1056/NEJMoa1701769
- Graf SA, Stevenson PA, Holmberg LA, et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol. 2015 Nov;26(11):2323–2328. doi: 10.1093/annonc/mdv364
- Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. [2021 Dec 13];39(12):1643–1653.e3. doi: 10.1016/j.ccell.2021.10.006
- Castel P, Toska E, Engelman JA, et al. The present and future of PI3K inhibitors for cancer therapy. Nat Cancer. 2021 Jun;2(6):587–597. doi: 10.1038/s43018-021-00218-4